Related references
Note: Only part of the references are listed.Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines
Matthew P. Goetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy
Aradhana Rani et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Rui-Mei Feng et al.
CANCER COMMUNICATIONS (2019)
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Andreas D. Hartkopf et al.
BREAST (2018)
Age at natural menopause and hypertension among middle-aged and older Chinese women
Lulu Song et al.
JOURNAL OF HYPERTENSION (2018)
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance
Adam M. Brufsky et al.
ONCOLOGIST (2018)
Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2-Advanced Breast Cancer
Anand A. Dalal et al.
ADVANCES IN THERAPY (2018)
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer
T. Reinert et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The changing landscape of clinical trial and approval processes in China
Qing Zhou et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis
Meng-Ting Chen et al.
SCIENTIFIC REPORTS (2017)
Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution
Junichiro Watanabe et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
Marta Bonotto et al.
BREAST (2017)
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
D. J. A. Lobbezoo et al.
ANNALS OF ONCOLOGY (2016)
Characteristics of breast cancer in Central China, literature review and comparison with USA
Chuang Chen et al.
BREAST (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Pattern of metastasis and outcome in patients with breast cancer
L. Gerratana et al.
CLINICAL & EXPERIMENTAL METASTASIS (2015)
Treatment patterns and duration in post-menopausal women with HR+/HER2-metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010)
Alexander R. Macalalad et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China
Qiancheng Hu et al.
PATHOLOGY & ONCOLOGY RESEARCH (2015)
Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
Fabrice Andre et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012
Elyse Swallow et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto et al.
ONCOLOGIST (2014)
A Nation-Wide Multicenter 10-Year (1999-2008) Retrospective Clinical Study of Endocrine Therapy for Chinese Females with Breast Cancer
Can Zhou et al.
PLOS ONE (2014)
Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors
Michael P. Lux et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe
Sue Gao et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives
Nagi S. El Saghir et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
Naoki Niikura et al.
ONCOLOGIST (2011)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer
Tiffany H. Svahn et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
National Breast Cancer Audit: Overview of invasive breast cancer management
Astrid V. Cuncins-Hearn et al.
ANZ JOURNAL OF SURGERY (2006)
Share Paper
